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Background:Hippocampal atrophy is a well-known feature of Alzheimer's disease (AD), but sensitivity and spec-
iﬁcity of hippocampal volumetry are limited. Neuropathological studies have shown that hippocampal subﬁelds
are differentially vulnerable to AD; hippocampal subﬁeld volumetry may thus prove to be more accurate than
global hippocampal volumetry to detect AD.
Methods: CA1, subiculum and other subﬁelds were manually delineated from 40 healthy controls, 18 AD, 17
amnestic Mild Cognitive Impairment (aMCI), and 8 semantic dementia (SD) patients using a previously devel-
oped high resolution MRI procedure. Non-parametric group comparisons and receiver operating characteristic
(ROC) analyseswere conducted. Complementary analyseswere conducted to evaluate differences of hemispher-
ic asymmetry and anterior-predominance between AD and SD patients and to distinguish aMCI patients with or
without β-amyloid deposition as assessed by Florbetapir-TEP.
Results: Global hippocampi were atrophied in all three patient groups and volume decreases were maxi-
mal in the CA1 subﬁeld (22% loss in aMCI, 27% in both AD and SD; all p b 0.001). In aMCI, CA1 volumetry
was more accurate than global hippocampal measurement to distinguish patients from controls (areas
under the ROC curve = 0.88 and 0.76, respectively; p = 0.05) and preliminary analyses suggest that it
was independent from the presence of β-amyloid deposition. In patients with SD, whereas the degree
of CA1 and subiculum atrophy was similar to that found in AD patients, hemispheric and anterior–posterior asym-
metry were signiﬁcantly more marked than in AD with greater involvement of the left and anterior hippocampal
subﬁelds.
Conclusions: The ﬁndings suggest that CA1 measurement is more sensitive than global hippocampal volumetry to
detect structural changes at the pre-dementia stage, although the predominance of CA1 atrophy does not appear
to be speciﬁc to AD pathophysiological processes.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. ; aMCI, amnesticMild Cognitive
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Hippocampal atrophy is a major feature of Alzheimer's disease (AD)
(Frisoni et al., 2010) that strongly correlates with AD neuropathology
(Bobinski et al., 1996; Jack et al., 2002). Using MRI, this atrophy is detect-
able prior to the diagnosis of AD, at the stage of amnestic Mild Cognitive
Impairment (aMCI) (Convit et al., 1997; Shi et al., 2009) or even earlier,
in asymptomatic elderly up to 10 years before the diagnosis of dementia
(Smith et al., 2007; Tondelli et al., 2012). Hippocampal volume has thus
been proposed as a neuroimaging biomarker for early AD diagnosis
(Albert et al., 2011; Dubois et al., 2010). Yet, the accuracy of thismeasure-
ment is limited by a moderate sensitivity and a rather low speciﬁcity to
AD pathophysiological processes (Frisoni et al., 2010). Indeed, hippocam-
pal atrophy has been highlighted in various neurological and psychiatricse. 
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disorders such as semantic dementia (SD) (Chan et al., 2001; Davies
et al., 2004; Desgranges et al., 2007; Galton et al., 2001; Nestor et al.,
2006).
Interestingly, neuropathological studies have shown a differential
vulnerability of hippocampal subﬁelds to AD, with CA1 showing the
earliest and strongest changes in terms of both neuroﬁbrillary tangles
(NFT) (Braak & Braak, 1991; Schönheit et al., 2004) and neuronal loss
(Rössler et al., 2002; West et al., 1994). In vivo measurement of CA1
atrophymay thus constitute a better surrogatemarker for AD pathology
than global hippocampal volumetry. Recently MRI acquisition and
processing techniques have been developed to assess the hippocampus
in more detail, including high-resolution hippocampus scans allowing
visualization and measurement of hippocampal subﬁelds (Mueller
et al., 2010; Pluta et al., 2012; Wisse et al., 2012).
In this study, we aimed at identifying the pattern of hippocampal
subﬁeld atrophy in patients with AD, aMCI and SD using a previously
developed technique based on high-resolution 3-Tesla MRI and
adapted delineation guidelines (La Joie et al., 2010). In addition we
assessed the diagnosis accuracy of these measures, hypothesizing that
speciﬁc measurement of the most vulnerable subﬁeld(s), e.g. CA1,
would be more accurate than global hippocampal volumetry to detect
AD-related hippocampal atrophy (Mueller et al., 2010; Pluta et al., 2012).
2. Material and methods
2.1. Participants
Eighty-three right-handed native French-speaking participants from
the IMAP project (La Joie et al., 2010) were included in the present
study: 40 healthy controls (HC), 17 aMCI patients, 18 AD patients, and
eight SD patients (see Table 1). They were all aged over 50 years, had
at least 7 years of education and had no history of alcoholism, drug
abuse, head trauma or psychiatric disorder.
All patients were recruited from local memory clinics and selected
according to corresponding internationally agreed criteria: Petersen's
criteria for aMCI (Petersen & Morris, 2005), NINCDS-ADRDA criteria
for probable Alzheimer's disease (McKhann et al., 1984) and Neary
et al. criteria for SD (Neary et al., 1998).
HCwere recruited from the community and performed in the normal
range on a neuropsychological examination assessing multiple domains
of cognition including episodic and semantic memory, executive and
visuo-spatial functions, language and praxis.
In addition to this clinically based selection, themajority of aMCI and
AD patients underwent a Florbetapir PET scan allowing to classify them
asβ-amyloid (Aβ)-positive or Aβ-negative as recommended in the new
research criteria for AD (Albert et al., 2011; Dubois et al., 2010) (see
Sections 2.3.3 and 2.4 below).Table 1
Demographic characteristics of participants.
Abbreviations: HC = healthy controls; aMCI = amnestic Mild Cognitive Impairment; AD = A
mental state examination; ANOVA = Analysis of variance.
All variables were compared using non-parametric tests.
a: Mattis scores were lower in AD and SD groups as compared to HC and aMCI but no differen
HC (n = 40) aMCI (n = 17)
Age
median (IQR)
66 (56, 72) 72 (69, 75)
Gender
females: n (%)
23 (58%) 9 (53%)
Years of education
median (IQR)
12 (9.5, 15) 10 (8, 12)
MMSE
median (IQR)
30 (29, 30) 27 (26, 28)
Mattis
median (IQR)
143 (142, 144) 137 (134, 138)The IMAP Study was approved by regional ethics committee (Comité
de Protection des Personnes Nord-Ouest III) and is registered with
ClinicalTrials.gov (number NCT01638949). All participants gave written
informed consent to the study prior to the investigation.
2.2. Neuroimaging data acquisition
All participants were scanned on the same MRI and PET cameras at
the Cyceron center (Caen, France).
2.2.1. MRI data
A high-resolution proton density-weighted MR sequence, perpen-
dicular to the long axis of the hippocampus (repetition time/echo
time = 3500/19 ms; ﬂip angle = 90°; 13 slices with 2 mm gap; slice
thickness = 2 mm; in-plane resolution = 0.375 × 0.375 mm) was ac-
quired on a Philips (Eindhoven, TheNetherlands) Achieva 3 T scanner. A
sagittal T1-weighted anatomical image was obtained beforehand using
a 3D fast ﬁeld echo sequence (repetition time/echo time = 20/4.6 ms;
ﬂip angle = 20°; 180 slices with no gap; slice thickness =1 mm in-
plane resolution = 1 × 1 mm) for the purpose of PET data preprocessing
and total intracranial volume (TIV) measurement (see below).
2.2.2. PET data
Florbetapir PET scans were acquired on a Discovery RX VCT 64
PET-CT device (General Electric Healthcare) with a resolution of
3.76 × 3.76 × 4.9 mm (ﬁeld of view = 157 mm). Forty-seven
planes were obtained with a voxel size of 2.7 × 2.7 × 3.27 mm. A trans-
mission scanwas performed for attenuation correction before the PET ac-
quisition. Participants underwent a 20-min PET scan, starting 50 min
after the intravenous injection of≈4 MBq/kg of Florbetapir.
2.3. Neuroimaging data processing
2.3.1. Hippocampal subﬁeld delineation
Three regions of interest (subiculum, CA1 and “other” subﬁelds —
encompassing CA2–CA3–CA4 and the dentate gyrus) were delineated
on both hippocampi of all individual high-resolutionMRI images, follow-
ing guidelines developed in the lab anddescribed in full details elsewhere
(La Joie et al., 2010). These guidelines were based on the anatomical
description from an atlas of the human hippocampus (Harding et al.,
1998). Delineations were performed on slices perpendicular to the long
axis of the hippocampus by a single rater, blind to the identity (age,
gender, clinical status) of the participants. Illustrations are provided in
Fig. 1 (see also Supplementary Fig. 1 for further details and additional
examples).
Unlike other groups with comparable high-resolution anisotropic
images (Mueller et al., 2010; Pluta et al., 2012) we delineated subﬁelds
along the head and body of the hippocampus (versus in the body onlylzheimer's disease; SD = semantic dementia; IQR = interquartile range; MMSE = mini-
ce was found between AD and SD.
AD (n = 18) SD (n = 8) Group comparison
66 (58, 76) 62.5 (59.5, 65.5) pANOVA = 0.027
aMCI N HC; aMCI N SD
12 (67%) 5 (63%) pChi-squared = 0.86
10 (7, 14) 12 (5.8, 15.5) pANOVA = 0.19
20.5 (20, 24) – pANOVA b 0.001
HC N aMCI N AD
123 (114, 128) 118 (111, 125.5) pANOVA b 0.001
HC N aMCI N AD, SDa
Fig. 1. Illustration of hippocampal subﬁeld delineation. Three regionsweremanually delineatedwithin each hippocampus: CA1 (blue), subiculum(green) and other (pink). Subﬁeldswere
delineated on 9 slices on average; for the purpose of illustration, examples are displayed on three slices along the anterior–posterior axis of the hippocampus. Images correspond to a
healthy control (left), a patient with Alzheimer's disease (middle) and a patient with semantic dementia (right). Images are in the neurological convention (right is right). Additional
examples are available in Supplementary Fig. 1.
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landmarks for subﬁelds delineation in the hippocampal head, we only
considered 3 regions of interest (therefore combining CA2–3–4 and the
dentate gyrus in the same “subﬁeld”) to ensure sufﬁcient reliability and
reproducibility (versus 4 or 5 subﬁelds in previous studies (Mueller
et al., 2010; Pluta et al., 2012)). As previously mentioned (Mueller et al.,
2010; Wisse et al., 2012), measurements of hippocampal subﬁelds not
only rely on landmarks derived from anatomical atlases, but also on
arbitrary rules that are ﬁxed by the investigators to reach a compromise
between reliability/reproducibility and validity. We acknowledge that
existing protocols show differences in their deﬁnition of hippocampal
subﬁelds but, in the absence of direct comparison between in vivo
imagingmethods (ideally including a confrontation to neuropathological
gold standard), the importance of these variations and their inﬂu-
ence on results remains unknown. However, a recently formed ini-
tiative led by experts in the ﬁeld is speciﬁcally meant to address
this issue and to potentially develop a uniﬁed hippocampal subﬁeld seg-
mentation protocol (to know more about this group, visit http://www.
hippocampalsubﬁelds.com/).
Moreover, it is to note that high-resolution scans such as those used
here are particularly prone to motion artifacts. To prevent the rejection
of a large proportion of individuals from analyses, a procedure was set-
tled to obtain high quality data from all individuals participating to im-
aging studies in our lab (including, but not restricted to the controls and
patients from the present article). Indeed, a visual quality check was
performed immediately after orwithin a fewdays of theMRI acquisition
and was carried out by the same person who analyzes the data (RLJ). If
image quality was considered insufﬁcient for subﬁeld delineation, the
scan was repeated within a few weeks during a second MRI session
(this occurred for about 15–20% of healthy controls and 30–40% of the
patients included in our total imaging cohort). Rarely, a third scan was
proposed. In the end, we failed to obtain an image of sufﬁcient quality
in some participants (roughly 5–10% of the controls and 15–20% of the
patients) as they could not come back for a repeated scan or because
the repeated scan(s) was/were still of insufﬁcient quality; in this case,
data were disregarded and excluded from all analyses. The 83 partici-
pants included in the present study had high quality data.2.3.2. Total intracranial volume (TIV)
Individual TIV values were obtained from the T1-weighted images
using theVBM5 toolbox implemented in the Statistical ParametricMap-
ping software (SPM5; Wellcome Trust Center for Neuroimaging, Insti-
tute of Neurology, London, England).2.3.3. Florbetapir PET
PET data were processed as described in reference (La Joie et al.,
2012). Brieﬂy, each individual T1-weighted MRI was segmented into
gray and white matter using the VBM5 toolbox (http://dbm.neuro.uni-
jena.de/vbm/vbm5-for-spm5/). These segments were used for partial
volume effect correction of raw PET data using the PMOD software.
Using the Statistical Parametric Mapping (SPM) software, resulting
images were coregistered onto corresponding MRI and normalized into
Montreal Neurological Institute (MNI) space using the deformation
parameters deﬁned from the VBM procedure. The mean Florbetapir
value in the cerebellum GM was extracted for each subject from the
normalized TEP images. Each Florbetapir image was then divided by its
corresponding mean cerebellar value, resulting in Florbetapir-PET SUVr
data. The global neocortical Florbetapir-PET SUVr value was then
computed for each subject from the Florbetapir-PET SUVr data using a
neocortex mask (including all regions but the cerebellum, hippocampus,
amygdala and subcortical gray nuclei).
2.4. Statistical analyses
Raw volumes of each hippocampal subﬁeld and of the whole hip-
pocampus (corresponding to the sum of the three subﬁelds) were
ﬁrst normalized by the TIV to account for inter-individual variability
in head size (normalized volume = 1000 × raw volume / TIV) and then
transformed into W-scores, i.e. age and gender-adjusted Z-scores (Jack
et al., 2002).W-scores provide information about the difference between
a patient's value and the value that would be expected in the control
group for his/her age and gender. In the present study, the use of W-
score is of particular interest because of the rather wide age range of
the participants and signiﬁcant age difference between aMCI and
both HC and SD groups (see Table 1). Due to the relative limited
size of the patient groups, Kruskal–Wallis non-parametric analyses
of variance (ANOVAs) were then performed on hippocampal subﬁeld
and whole hippocampus W-scores, and when a signiﬁcant effect of
group was found (p b 0.05), Mann–Whitney U tests were used for
pairwise comparisons.
As previous studies reported a stronger hemispheric asymmetry
and an anterior predominance of hippocampal atrophy in SD com-
pared with AD (Chan et al., 2001; Nestor et al., 2006), complementa-
ry indices were calculated to characterize these gradients within
each subﬁeld. First, hemispheric asymmetry was measured as the
absolute difference between left and right hippocampal volumes
expressed as a percentage of the total volume (100 x | right
volume – left volume | / bilateral hippocampal volume). Second,
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centage of each subﬁeld volume located in the anterior hippocam-
pus (100 x anterior volume / total hippocampal volume), with
the anterior portion corresponding to the hippocampal head (Jack
et al., 1997; Malykhin et al., 2007; Pruessner & Li, 2000). These in-
dices were compared between HC, AD and SD using Kruskal–Wallis
ANOVA and Mann–Whitney U tests.
Discriminant analyses were performed to assess the ability of
each hippocampal subﬁeld and of the whole hippocampus volume
to distinguish i) AD patients from HC, ii) aMCI patients from HC,
and iii) SD patients from AD. Areas Under the receiver operating
characteristic Curve (AUC) of global hippocampus versus subﬁeld
volumes were then compared to test the hypothesis that subﬁeld is
more accurate than global hippocampal volumetry to discriminate
between the groups.
Finally, preliminary analyses were conducted to assess the impact
of the presence of Aβ on the different hippocampal volumes. All AD
patients (n = 18) and 15 patients with aMCI (out of 17) underwent
a Florbetapir PET scan and were classiﬁed using a previously deter-
mined Florbetapir neocortical SUVr of 1.1 (see reference (La Joie
et al., 2012)). All AD patients were classiﬁed as Aβ-positive and 9
aMCI patients (60% of aMCI patients who underwent Florbetapir-
PET) were classiﬁed as Aβ-positive. Aβ-positive and Aβ-negative
aMCI did not differ in age, gender or education (all p-values N 0.8). Statis-
tical analyses on hippocampal volumes included both Spearman's corre-
lation between Aβ load and hippocampal atrophy within the 15 aMCI
patients, and comparisons between Aβ-positive versus Aβ-negative
aMCI, andbetween each subgroup andHC. For the latter analysis, because
aMCI was signiﬁcantly older than the whole HC group (see Table 1), a
subgroup of age, gender and education-matched HC (n = 28) was used.Fig. 2. Between-group comparisons of hippocampal measurements. Abbreviations: HC = hea
SD = semantic dementia. Volumes are expressed as W-scores (i.e. age- and gender-adjusted
regions and post-hoc tests were performed with the Mann–Whitney test (t: p b 0.10; *: p b 03. Results
3.1. Atrophy of hippocampal subﬁelds in patients
Comparisons ofW-scores are illustrated in Fig. 2. Brieﬂy, the volume
of the whole hippocampus was signiﬁcantly decreased in all three
patient groups as compared to HC (mean volume loss = −12% for
aMCI, −22% for AD and −17% for SD). In aMCI, atrophy was highly
signiﬁcant in CA1 (−22%, p b 0.001) and to a lesser extent in the
subiculum (−17%, p = 0.01). In AD, volume decreases were highly
signiﬁcant (p b 0.001) for all three subﬁelds, but atrophy in the other
region (−17%) was signiﬁcantly lower (p b 0.005 using Wilcoxon
rank-sum test) than in both CA1 and subiculum (both −27%). In the
SD group, both CA1 and subiculum volumes were signiﬁcantly reduced
relative to HC (−27% and−24% respectively, both p b 0.001). Sim-
ilarly to the ﬁndings in the AD group, comparing degrees of atrophy
(expressed as W-scores) between the three subﬁelds in SD showed
that both CA1 and subiculum were signiﬁcantly more affected than
the other subﬁeld (both p b 0.05 Wilcoxon rank-sum test). None of
the volumes differed between AD and SD patients (all p values N 0.15).
Note that the main results were unchanged when performing compari-
sons on raw volumes or TIV-normalized volumes instead of age- and
gender-adjustedW-scores as presented here (see Supplementary Fig. 2).
3.2. Hemispheric asymmetry and anterior–posterior gradient in AD and SD
The results of the between-group comparisons of the hippocam-
pal indices are reported in Table 2. Greater hemispheric asymmetry
was found in SD patients compared to HC for all volumes (all p
values b 0.03). Asymmetry was signiﬁcantly stronger in SD than inlthy controls; aMCI = amnestic Mild Cognitive Impairment; AD = Alzheimer's disease;
Z-scores as compared to the control group). Kruskal–Wallis ANOVA was signiﬁcant for all
.05; **: p b 0.01; ***: p b 0.001).
Table 2
Hemispheric asymmetry and anterior–posterior gradients of subﬁeld atrophy in AD and SD patients. Abbreviations: HC = healthy controls; AD = Alzheimer's disease; SD = semantic
dementia; IQR = interquartile range. ANOVA were conducted with the Kruskal & Wallis H test and when signiﬁcant (p b 0.05), two-by-two comparisons were assessed with the
Mann–Whitney test. Signiﬁcant (p b 0.05) results are shown in bold. Increased hemispheric asymmetry indicates a stronger left/right volume difference but not the direction of this
difference. Increased anterior–posterior gradient index indicates an increase in the volume of the anterior hippocampal compared to that of the total hippocampal volume. See main
text (Section 2.4) for further information.
Values: median (IQR) Statistical comparisons
HC AD SD ANOVA HC/AD HC/SD AD/SD
Hemispheric asymmetry
CA1 5.4
(1.8, 8.5)
7.8
(4.2, 17.0)
15.3
(13.1, 18.5)
H = 14.7
p b 10−3
Z = 1.94
p = 0.05
Z = 3.67
p b 10−3
Z = 1.86
p = 0.06
Subiculum 3.8
(1.6, 6.5)
6.6
(1.8, 8.1)
17.7
(12.7, 23.8)
H = 16.1
p b 10−3
Z = 1.64
p = 0.10
Z = 3.91
p b 10−3
Z = 2.42
p = 0.02
Other 5.2
(2.8, 9.8)
5.1
(1.9, 8.1)
11.4
(7.2, 14.4)
H = 7.2
p = 0.03
Z = −0.82
p = 0.42
Z = 2.31
p = 0.021
Z = 2.53
p = 0.01
Global hippocampus 2.1
(1.2, 4.0)
4.7
(2.8, 7.1)
14.2
(11.2, 16.1)
H = 27.1
p b 10−3
Z = 3.17
p = 0.002
Z = 4.41
p b 10−3
Z = 3.25
p = 0.001
Anterior–posterior gradient
CA1 66.2
(63.4, 70.0)
66.6
(59.7, 70.1)
56.5
(52.9, 57.6)
H = 14.7
p b 10−3
Z = −0.33
p = 0.74
Z = −3.80
p b 10−3
Z = 3.08
p = 0.002
Subiculum 57.2
(53.2, 61.5)
60.1
(53.3, 65.6)
52.4
(44.8, 54.9)
H = 8.3
p = 0.02
Z = 1.02
p = 0.31
Z = 2.59
p = 0.01
Z = 2.47
p = 0.01
Other 62.8
(57.5, 66.7)
65.8
(57.1, 70.4)
59.7
(55.5, 61.9)
H = 3.03
p = 0.22
– – –
Global hippocampus 62.4
(59.0, 65.1)
64.6
(58.2, 68.5)
55.6
(52.0, 59.0)
H = 9.3
p = 0.009
Z = 0.60
p = 0.55
Z = 2.95
p = 0.003
Z = 2.53
p = 0.01
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other (p = 0.01) and a trend was found for CA1 (p = 0.06).
Finally, the anterior–posterior index was signiﬁcantly lower in SD
compared to both HC and AD for the whole hippocampus, CA1 and
subiculum, indicating a predominance of atrophy in the anterior hippo-
campus in SD.3.3. Evaluation of diagnostic accuracy
For the AD versus HC discrimination, the AUC of all subﬁelds was
signiﬁcantly higher than 0.5 (mean [95% CI] = 0.92 [0.85–0.99] for
CA1, 0.88 [0.76–1] for subiculum, 0.81 [0.67–0.94] for other) but
none of them was signiﬁcantly higher than that of the wholeFig. 3. ROC Curve for CA1 and total hippocampal volume in aMCI patients versus HC. ROC
curves for CA1 (blue) and total hippocampal volume (gray) in the comparison between
healthy controls (HC) and patients with amnestic Mild Cognitive Impairment (aMCI).
The area under the curve (AUC) is signiﬁcantly higher (p = 0.05) for CA1 (AUC = 0.881)
than for total hippocampal volume (0.763).hippocampus (0.91 [0.78–1]). For the discrimination between HC
and aMCI, the AUC of CA1 (0.88 [0.78–0.98]) was signiﬁcantly higher
than 0.5 and higher than the AUC of the whole hippocampus (0.76
[0.60–0.93], p = 0.05; see Fig. 3), whereas the subiculum AUC
(0.74 [0.59–0.90]) was signiﬁcantly higher than 0.5 but did not per-
form better than the whole hippocampus, and the AUC for the other
subﬁelds was not signiﬁcantly different from 0.5 (0.53 [0.34–0.72]).
Finally, none of the volume measurements were allowed to sepa-
rate AD from SD as none of the AUCs was signiﬁcantly different
from 0.5: 0.51 [0.27–0.74] for CA1, 0.64 [0.43–0.85] for subiculum,
0.69 [0.45–0.94] for other, and 0.69 [0.47–0.90] for the whole
hippocampus.
3.4. Volume of hippocampal subﬁelds versus neocortical amyloid load in
aMCI patients
A Kruskal–Wallis ANOVA with three groups (HC, Aβ-positive aMCI,
Aβ-negative aMCI) was performed on TIV-normalized hippocampalFig. 4. CA1 atrophy in aMCI patients classiﬁed as Aβ-positive or Aβ-negative
according to their neocortical Florbetapir SUVr. Abbreviations: HC = healthy
controls; Aβ + aMCI = β-amyloid—positive patients with amnestic Mild Cognitive
Impairment; Aβ − aMCI = β-amyloid—negative patients with amnestic Mild Cognitive
Impairment. For this analysis, a subsample of 28 age-, gender-, and education-matched HC
was selected. Kruskal–Wallis ANOVA was signiﬁcant (p = 0.001) and post-hoc tests were
performed with the Mann–Whitney test (*: p b 0.05; ***: p b 0.001).
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(H = 13.8; p = 0.001), subiculum (H = 5.99; p = 0.05) and glob-
al hippocampus (H = 5.98; p = 0.05). Post-hoc analyses revealed that
Aβ-positive aMCI had signiﬁcantly lower CA1 (p b 0.001), subiculum
(p = 0.01) and hippocampal volumes (p = 0.01) as compared to HC,
while Aβ-negative aMCI only showed lower CA1 volume (p = 0.04) as
compared to HC, as illustrated in Fig. 4. The direct comparison between
Aβ-positive aMCI and Aβ-negative aMCI did not show any signiﬁcant dif-
ference (all p values N 0.25). Similarly, none of the volumes signiﬁcantly
correlated with Florbetapir neocortical SUVr in the whole group
of 15 aMCI (CA1: Spearman's ρ = −0.34, p = 0.22; subiculum
ρ = −0.26, p = 0.34; other ρ = −0.01, p = 0.96; whole hippo-
campus ρ = −0.23, p = 0.41). All the results remained unchanged
when using W-scores instead of TIV-normalized volumes (data not
shown).
4. Discussion
Using a high-resolution sequence on a 3 T MRI scanner, hippocam-
pal subﬁelds were delineated in healthy controls and patients with
aMCI, AD or SD. Analyses showed that the pathologies had a differential
effect on the hippocampal subﬁelds, with a preferential involvement
(i.e. stronger and earlier atrophy) of CA1 and subiculum. This pattern
was not discriminant at the dementia stage as i) no differences were
found between AD and SD and ii) hippocampal subﬁelds did not
perform better than the whole hippocampus in discriminating AD
from HC. By contrast, at the aMCI stage, CA1 volume loss predominated
andwas found to better discriminate aMCI patients fromHC than global
hippocampal volume.
4.1. Hippocampal subﬁeld atrophy in AD
The ﬁnding of a differential atrophy of the hippocampal subﬁelds
in AD, with a stronger and earlier alteration of CA1 and subiculum, is
in agreement with neuropathological studies (Braak & Braak, 1991;
Rössler et al., 2002; Schönheit et al., 2004; West et al., 1994). For in-
stance, West et al. (1994) reported a reduction in the number of neu-
rons in AD patients compared to HC of 68% in CA1, 47% in the
subiculum and 25% in the hilus of the dentate gyrus. The higher
vulnerability of CA1 neurons is likely to be at least partly due to the
neuroﬁbrillary pathology as the CA1 subﬁeld is the ﬁrst hippocampal
area to be affected by NFT (Braak & Braak, 1991; Schönheit et al.,
2004). Moreover, several studies have reported a strong negative
correlation between neuronal counts and NFT number in the CA1
subﬁeld (Fukutani et al., 2000; Von Gunten et al., 2006) suggesting
that the progression of brain atrophy and the progression of NFT
are strongly associated (Whitwell et al., 2008).
Using a variety of neuroimaging approaches such as radial atrophy
(Frisoni et al., 2006), large-deformation high-dimensional brain map-
ping (Wang et al., 2003), voxel-based morphometry (Chételat et al.,
2008) or manual delineation (Mueller et al., 2010), the predominance
of atrophy in CA1 (and to a lesser extent in the subiculum) in patients
with clinical AD or aMCI has already been shown in vivo. In the present
study, we conﬁrmed this point using a reﬁned methodology in patients
with both a clinical diagnosis of AD and a positive Florbetapir PET-scan.
Our study showed that all subﬁelds were atrophied at this AD dementia
stage and subﬁeld measurements were not more accurate than the
global hippocampus in discriminating AD from HC. By contrast, and in
agreement with previous volumetric studies (Hanseeuw, 2011;
Mueller et al., 2010; Pluta et al., 2012), we showed that subﬁeld mea-
surements were more accurate than global hippocampal volumetry to
differentiate aMCI from HC, highlighting the interest of these methods
for early AD detection. However, discrepancies exist as regards to the
area of largest difference between HC and aMCI patients (CA1 (Pluta
et al., 2012), CA1–CA2 transition area (Mueller et al., 2010) or
subiculum (Hanseeuw, 2011), probably reﬂecting variations in theanatomical landmarks used for subﬁeld delineation as further discussed
in previous publications (La Joie et al., 2010;Wisse et al., 2012) (see the
method Section 2.3.1 for further discussion).
4.2. Comparison of the pattern of hippocampal atrophy in AD versus SD
AD and SD patients did not differ in terms of subﬁeld volumetry.
Although the absence of signiﬁcant difference could be due to a lack of
statistical power, preferential atrophy of both CA1 and subiculum was
found in both groups and this ﬁnding is consistent with a recent
surface-based study of the hippocampus in SD (Lindberg et al., 2012).
Yet, the pathological substrate of hippocampal atrophy in SD is not
clear, notably because patients with SD can presentwith heterogeneous
pathological features (Davies et al., 2005). Despite this variability, a se-
vere neuronal loss in the CA1 subﬁeld together with a preservation of
neurons in the dentate gyrus, consistent with our imaging ﬁndings,
was reported independently of the histopathological subtypes (Davies
et al., 2005).
Contrastingly, hippocampal atrophy differed between SD andADpa-
tients in terms of hemispheric and anterior–posterior asymmetry, in
agreement with previous reports (Chan et al., 2001; Davies et al.,
2004; Galton, 2001; Nestor et al., 2006), and we showed that these
two gradients were mostly independent of subﬁelds. Previous authors
(Chan et al., 2001; Davies et al., 2004; Galton, 2001) hypothesized that
this asymmetric nature of hippocampal atrophy in SD could partly ex-
plain the intriguing relative preservation of episodic memory in SD as
compared to AD (Hornberger & Piguet, 2012) in spite of similarly severe
hippocampal atrophy (Pleizier et al., 2012). According to these authors,
the relatively spared hippocampal areas (posterior areas and most of
the time the right hippocampus) in SD could therefore be sufﬁcient to
support essential episodic memory abilities (Chan et al., 2001; Davies
et al., 2004; Galton, 2001). Alternatively, it has been proposed (Nestor
et al., 2006) that differential alterations of cortical areas that are crucial
for episodic memory, such as the posterior cingulate cortex (PCC) that
shows a strong hypometabolism in AD but not in SD, are more likely to
account for the differential alteration of episodic memory between AD
and SD. Yet, these two hypotheses are not necessarily independent as
hippocampal atrophy has been shown to induce PCC hypometabolism
through a disconnection process in AD (Villain et al., 2008). Besides, the
connectivity of the hippocampus varies along its anterior–posterior
axis, with the posterior part being more strongly connected to the PCC
(Poppenk et al., 2013). It is thus possible that the predominance of
atrophy in the anterior hippocampus in SD at least partly accounts
for differences in distant cortical alterations (e.g. the lack of PCC
hypometabolism) compared to AD, themselves underlying differ-
ences in the cognitive deﬁcits. This would also be consistent with
the idea that SD and AD target two large-scale brain networks that
would underlie different cognitive functions and differentially in-
clude anterior versus posterior hippocampi (Ranganath & Ritchey,
2012).
4.3. Relationships between hippocampal subﬁeld atrophy and Aβ in aMCI
Because the presence of Aβ deposition signiﬁcantly increases the
likelihood of having AD pathology in patients with aMCI according to
current diagnosis recommendations (Albert et al., 2011; Dubois et al.,
2010), we also investigated hippocampal subﬁeld atrophy in aMCI pa-
tients as a function of Aβ load. We did not ﬁnd a signiﬁcant inﬂuence
of the presence of Aβ on the pattern of hippocampal subﬁeld atrophy
as both Aβ-positive and Aβ-negative aMCI showed a predominant atro-
phy of the CA1 subﬁeld (Fig. 4). However, these ﬁndings should be con-
sidered as preliminary given the small size of the aMCI samples when
dichotomized in Aβ-positive and Aβ-negative. Yet, this ﬁnding is in
line with recent studies showing that AD-type atrophy and/or
hypometabolism can be found in both Aβ-negative healthy controls
(Jack et al., 2012) and Aβ-negative MCI patients (Prestia et al., 2013).
161R. La Joie et al. / NeuroImage: Clinical 3 (2013) 155–162While it may reﬂect methodological issues related to biomarker mea-
surements (Jack et al., 2013), it is possible that CA1 atrophy in Aβ-
negative patients reﬂect non-AD pathophysiological processes. This
would be consistent with the ﬁnding of CA1 atrophy in other disorders
(Gemmell et al., 2012; Jack et al., 2002; Zarow et al., 2012) and the idea
that aMCI in Aβ-negative patients is unlikely due to AD etiology (Albert
et al., 2011). Alternatively, recent ﬁndings suggest that neuronal injury
biomarkers known to be closely related to tau pathology such as hippo-
campal atrophy (see above), may occur independently and possibly prior
to Aβ in the course of AD (Chételat, 2013; Knopman et al., 2013). This
would rather support hypotheses suggesting that tau pathology could
occur independently fromAβ accumulation (Small, 2008), than the amy-
loid hypothesis where tau-related neurodegeneration is supposed to ap-
pear downstream to Aβ. Further investigations are needed not only to
test these hypotheses but also to replicate our ﬁndings regarding the re-
lationships between hippocampal subﬁeld atrophy and Aβ in a larger
sample given the limited size of our aMCI subgroups.
It should also be noted that subﬁeld volumetry as performed in the
present study only provides approximations of the exact volumes of
the hippocampal subﬁelds, based on anatomical landmarks derived
from histological atlases (see the method Section 2.3.1 for further
discussion).
4.4. Conclusion
Overall, our ﬁndings in AD and SD are consistent with the topogra-
phy of neuronal loss described in post-mortem studies as well as with
previous imaging studies that used different methods. They suggest
that hippocampal subﬁeld volumetry is a promising biomarker for
early AD detection at a predementia or even presymptomatic stage,
especially with the widespread use of high-resolution MR sequences
in the last years (Mueller et al., 2010; Wisse et al., 2012) and the on-
going development of automatic subﬁeld segmentation procedures
(Van Leemput et al., 2009; Yushkevich et al., 2010). Further studies
are therefore needed to assess the diagnostic and prognostic accuracies
of this novel technique in larger samples and in comparison to other
established AD biomarkers.
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